Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7186972 | 0.90 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL12846997 | 0.84 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL30027753 | 0.82 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL12830396 | 0.82 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL29130829 | 0.82 | HTT (0.53) | GAACA1CA2CA12CA3 | |
| SCHEMBL9767634 | 0.80 | GAA (0.48) | GAACA1CA2CA12CA3 | |
| SCHEMBL6490 | 0.80 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL22105941 | 0.79 | GAA (0.46) | GAACA1CA2CA12CA3 | |
| SCHEMBL2849488 | 0.79 | GAA (0.46) | GAACA1CA2CA12CA3 | |
| SCHEMBL16852304 | 0.79 | TLR9 (0.47) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622873-B1 | METHOD FOR PRODUCING RAC-1-{4-[2-HYDROXY-3-(5-QUINOLYLOXY)PROPYL]-PIPERAZIN-1-YL}-2,2-DIPHENYLETHAN-1-ONE FUMARATE | BAYER SCHERING PHARMA AG (DE) | 2010-01-13 | — | — | EP | claimed |
| US-5087773-A | Reacting with toluenesulfonic anhydride, contacting with telluride or selenide | SYRACUSE UNIVERSITY (US) | 1992-02-11 | — | — | US | claimed |
| US-9056136-B2 | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia | NATURAL PHARMACIA INTERNATIONAL, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2081910-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009050218-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050221-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050243-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050244-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| US-20080085237-A1 | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-04-10 | — | — | US | disclosed |
| CN-1227249-C | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-16 | — | — | CN | disclosed |
| CN-1349528-A | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2002-05-15 | — | — | CN | disclosed |
| US-5866036-A | HIGH POLARIZATION; HIGH SPEED SWITCHES; HIGH BIREFRINGENCE | DISPLAYTECH, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5380460-A | Ferroelectric liquid crystal compounds containing chiral haloalkoxy tail units and compositions containing them | DISPLAYTECH, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993006192-A1 | FERROELECTRIC LIQUID CRYSTAL COMPOUNDS CONTAINING CHIRAL HALOALKOXY TAIL UNITS AND COMPOSITIONS CONTAINING THEM | DISPLAYTECH, INCORPORATED (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120883-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | GAA 780/4885CA1 4551/4885CA2 2488/4885 |
| US-20080085237-A1 | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia | HIF1A, HIF1AN, NME4 | GAA 2007/4885CA1 408/4885CA2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.